Zacks Investment Research on MSN9h
FDA Approves Novartis Drug for Rare Kidney Disease TreatmentNovartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
Zacks Investment Research on MSN11h
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in CardiomyopathyAlnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its ...
Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...
Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...
The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...
Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...
Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...
conducted a review of the Food and Drug Administration (FDA) accelerated approval pathway for prescription drugs, to better understand the extent to which the FDA’s review varied throughout the ...
Efforts to establish the safely profile of drugs begin early in their development, with in vitro and in vivo toxicity testing, and continue through clinical trials leading up to drug approval and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback